Utility of serum complement factors C3 and C4 as biomarkers during therapeutic management of giant cell arteritis
There is a strong unmet need for biomarkers in giant cell arteritis (GCA), as C-reactive protein (CRP) may be unreliable in patients treated with Tocilizumab (TCZ). We aimed to assess whether C3 and C4 are useful biomarkers in GCA patients, particularly in those treated with TCZ. We retrospectively...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
2023
|
| In: |
Scandinavian journal of rheumatology
Year: 2023, Volume: 52, Issue: 3, Pages: 276-282 |
| ISSN: | 1502-7732 |
| DOI: | 10.1080/03009742.2022.2047311 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1080/03009742.2022.2047311 Verlag, lizenzpflichtig, Volltext: https://www.tandfonline.com/doi/full/10.1080/03009742.2022.2047311 
|
| Author Notes: | E Conticini, B Hellmich, B Frediani, E Csernok and C Löffler |
MARC
| LEADER | 00000caa a22000002c 4500 | ||
|---|---|---|---|
| 001 | 1891383000 | ||
| 003 | DE-627 | ||
| 005 | 20241205142725.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240617s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/03009742.2022.2047311 |2 doi | |
| 035 | |a (DE-627)1891383000 | ||
| 035 | |a (DE-599)KXP1891383000 | ||
| 035 | |a (OCoLC)1475299789 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Conticini, Edoardo |e VerfasserIn |0 (DE-588)133326321X |0 (DE-627)1891383736 |4 aut | |
| 245 | 1 | 0 | |a Utility of serum complement factors C3 and C4 as biomarkers during therapeutic management of giant cell arteritis |c E Conticini, B Hellmich, B Frediani, E Csernok and C Löffler |
| 246 | 3 | 3 | |a Utility of serum complement factors C three and C four as biomarkers during therapeutic management of giant cell arteritis |
| 264 | 1 | |c 2023 | |
| 300 | |a 7 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Online veröffentlicht: 06. April 2022 | ||
| 500 | |a Gesehen am 17.06.2024 | ||
| 520 | |a There is a strong unmet need for biomarkers in giant cell arteritis (GCA), as C-reactive protein (CRP) may be unreliable in patients treated with Tocilizumab (TCZ). We aimed to assess whether C3 and C4 are useful biomarkers in GCA patients, particularly in those treated with TCZ. We retrospectively enrolled all patients who underwent C3 and C4 measurement at baseline. All patients were evaluated at 3, 6, 12, and 24 months after diagnosis, as part of routine follow-up. Two assessments after the end of the observational period, in case of further relapses, were also included. At baseline, mean ± sd levels (mg/dL) of C3 (133 ± 28.99) and C4 (25.9 ± 9.04) were within normal ranges. During follow-up, C3 and C4 decreased in patients attaining remission (107.07 ± 19.86, p = 0.0006; 19.86 ± 10.27, p = 0.01, respectively) and sustained remission (95.85 ± 18.04, p = 0.001; 15.61 ± 9.75, p = 0.006). In TCZ-treated patients, even stronger decreases in C3 (83.11 ± 19.66, p = 0.001) and C4 (8.26 ± 3.83, p < 0.0001) were observed, and their values were not correlated with CRP or erythrocyte sedimentation rate. C3 and C4 do not seem useful in the diagnosis of GCA, as normal values do not rule out active vasculitis. However, C3 and C4 correlate with disease activity. As the low C4 levels found in TCZ-treated patients are not correlated with CRP, C4 should be evaluated as a potential biomarker of disease activity and treatment response. | ||
| 700 | 1 | |a Hellmich, Bernhard |d 1886- |e VerfasserIn |0 (DE-588)130800554 |0 (DE-627)707569206 |0 (DE-576)298349027 |4 aut | |
| 700 | 1 | |a Frediani, B |e VerfasserIn |4 aut | |
| 700 | 1 | |a Csernok, E |e VerfasserIn |4 aut | |
| 700 | 1 | |a Löffler, Christian |d 1982- |e VerfasserIn |0 (DE-588)138751927 |0 (DE-627)605700486 |0 (DE-576)30864266X |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Scandinavian journal of rheumatology |d Abingdon : Taylor & Francis, 1972 |g 52(2023), 3, Seite 276-282 |h Online-Ressource |w (DE-627)306359197 |w (DE-600)1497111-2 |w (DE-576)103746838 |x 1502-7732 |7 nnas |a Utility of serum complement factors C3 and C4 as biomarkers during therapeutic management of giant cell arteritis |
| 773 | 1 | 8 | |g volume:52 |g year:2023 |g number:3 |g pages:276-282 |g extent:7 |a Utility of serum complement factors C3 and C4 as biomarkers during therapeutic management of giant cell arteritis |
| 856 | 4 | 0 | |u https://doi.org/10.1080/03009742.2022.2047311 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.tandfonline.com/doi/full/10.1080/03009742.2022.2047311 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20240617 | ||
| 993 | |a Article | ||
| 994 | |a 2023 | ||
| 998 | |g 138751927 |a Löffler, Christian |m 138751927:Löffler, Christian |d 60000 |d 61400 |d 60000 |e 60000PL138751927 |e 61400PL138751927 |e 60000PL138751927 |k 0/60000/ |k 1/60000/61400/ |k 0/60000/ |p 5 |y j | ||
| 999 | |a KXP-PPN1891383000 |e 453954926X | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"person":[{"display":"Conticini, Edoardo","family":"Conticini","given":"Edoardo","roleDisplay":"VerfasserIn","role":"aut"},{"given":"Bernhard","roleDisplay":"VerfasserIn","role":"aut","display":"Hellmich, Bernhard","family":"Hellmich"},{"display":"Frediani, B","family":"Frediani","role":"aut","given":"B","roleDisplay":"VerfasserIn"},{"roleDisplay":"VerfasserIn","given":"E","role":"aut","family":"Csernok","display":"Csernok, E"},{"display":"Löffler, Christian","family":"Löffler","role":"aut","given":"Christian","roleDisplay":"VerfasserIn"}],"physDesc":[{"extent":"7 S."}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"relHost":[{"id":{"zdb":["1497111-2"],"eki":["306359197"],"issn":["1502-7732"]},"note":["Gesehen am 09.09.15"],"recId":"306359197","type":{"bibl":"periodical","media":"Online-Ressource"},"disp":"Utility of serum complement factors C3 and C4 as biomarkers during therapeutic management of giant cell arteritisScandinavian journal of rheumatology","physDesc":[{"extent":"Online-Ressource"}],"part":{"issue":"3","pages":"276-282","text":"52(2023), 3, Seite 276-282","year":"2023","volume":"52","extent":"7"},"language":["eng"],"origin":[{"dateIssuedDisp":"1972-","publisher":"Taylor & Francis","publisherPlace":"Abingdon ; London [u.a.] Informa Healthcare","dateIssuedKey":"1972"}],"pubHistory":["1.1972 -"],"title":[{"title_sort":"Scandinavian journal of rheumatology","title":"Scandinavian journal of rheumatology"}]}],"recId":"1891383000","note":["Online veröffentlicht: 06. April 2022","Gesehen am 17.06.2024"],"id":{"eki":["1891383000"],"doi":["10.1080/03009742.2022.2047311"]},"title":[{"title_sort":"Utility of serum complement factors C3 and C4 as biomarkers during therapeutic management of giant cell arteritis","title":"Utility of serum complement factors C3 and C4 as biomarkers during therapeutic management of giant cell arteritis"}],"titleAlt":[{"title":"Utility of serum complement factors C three and C four as biomarkers during therapeutic management of giant cell arteritis"}],"origin":[{"dateIssuedKey":"2023","dateIssuedDisp":"2023"}],"name":{"displayForm":["E Conticini, B Hellmich, B Frediani, E Csernok and C Löffler"]},"language":["eng"]} | ||
| SRT | |a CONTICINIEUTILITYOFS2023 | ||